Products
Online Inquiry
LY-2584702 free base
Cat. No.:
0225LY-0574
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
LY2584702 functions as an ATP-competitive and selective p70S6K inhibitor with an IC50 of 4 nM.
Synonym:
1082949-67-4; 4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methylimidazol-2-yl]piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine; 1H-Pyrazolo(3,4-d)pyrimidine, 4-(4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)-1-piperidinyl)-; 4-(4-(4-(4-Fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)piperidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine; 4-(4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methylimidazol-2-yl)piperidin-1-yl)-1H-pyrazolo(3,4-d)pyrimidine; 4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)-1-(1H-pyrazolo(3,4-d)pyrimidin-4-yl)piperidine
CAS No.:
1082949-67-4
Compound CID:
25118925
Formula:
C21H19F4N7
Formula Weight:
445.42
Specification
Targets&IC50:
p70 S6K: 4 nM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LY-2584702 free base can be used in oncology research to evaluate the selective inhibition of p70 S6 kinase (p70S6K).
Library Information
Target:
S6 Kinase; mTOR
Receptor:
mTOR (p70S6K); RSK
Pathways:
MAPK; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-8
Plate Location:
d8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
2mM DMSO
DMSO Max Solubility:
1 mg/mL; 2.25 mM
